SETD2 and cancer: This may support the belief that the HIF-1α may control angiogenesis and other metabolism by upregulating genes other than the IL-33 and the VEGF, and it regulates different paths in more complex actions that need to test the dependency of each biomarker, since this may improve the HIF-1 inhibitors used in specific cancer therapy.